By Bhanvi Satija LONDON, July 20 (Reuters) – Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oil prices hold near six-week highs on US-Iran attacks
By Shadia Nasralla LONDON, Sept 7 (Reuters) - Oil prices were near six-week highs on…
Paper cups are leaching microplastics into coffees, tests show
Sydney (dpa) - Concerns about the environmental and health effects of plastic packaging have prompted…
DMRC Wins HR for the Greater Good 2026 Award at XLRI’s HR for the Greater Good Conclave 2.0
Jamshedpur (Jharkhand) [India], September 7: XLRI – Xavier School of Management, through its Centre for…
